<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673049</url>
  </required_header>
  <id_info>
    <org_study_id>A4021018</org_study_id>
    <nct_id>NCT00673049</nct_id>
  </id_info>
  <brief_title>Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer</brief_title>
  <acronym>NSCLC</acronym>
  <official_title>Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With CP-751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to test a clinical benefit of the addition of CP 751,871 to
      erlotinib therapy in patients with advanced NSCLC of non adenocarcinoma histology. The
      primary endpoint is Overall Survival (OS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was terminated on March 8, 2010 due to an analysis by an independent Data Safety
      Monitoring Committee (DSMC) indicating that the addition of CP-751,871 [figitumumab] to
      erlotinib [Tarceva] would be unlikely to meet the primary endpoint of improving overall
      survival when compared to erlotinib alone.

      This Oncology study continues as terminated, however for ethical reasons some patients, noted
      with resultant benefit, continue receiving treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description.
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Baseline, assessed every cycle until disease progression and then every 4 weeks until death, up to 30.65 months</time_frame>
    <description>The time from date of randomization to date of death due to any cause. For participants who were alive, overall survival was censored at the last contact.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline, 6, 9, 12, 15, 18 weeks after randomization, thereafter assessed every 6 weeks until disease progression during treatment (or every 8 weeks until disease progression during off-treatment), up to 29.7 months</time_frame>
    <description>Time from randomization to date of first documentation of progression or death due to any cause, whichever came first. Participants last known to be alive and progression-free, who had a baseline and at least 1 on-study disease assessment, were censored at last disease assessment verifying lack of progression. Progression was determined by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, as a 20% increase in the sum of the longest diameter of target lesions, or target lesions over nadir, unequivocal progression of non-target disease, or the appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Objective Response</measure>
    <time_frame>Baseline, 6, 9, 12, 15, 18 weeks after randomization, thereafter assessed every 6 weeks until disease progression during treatment (or every 8 weeks until disease progression during off-treatment), up to 29.7 months</time_frame>
    <description>Percentage of participants with objective response (OR) based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. CR are defined as complete disappearance of all lesions (target and/or non target). PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for Figitumumab</measure>
    <time_frame>Cycle 1 (Day 1 [predose], Day 2 [1 hour after end of infusion] ), Cycles 2, 4, 6 (predose), Cycle 5 (predose, 1 hour after end of infusion) for figi plus erlo group; Cycles 1, 2,4 (predose) for erlo, then figi group</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Trough Concentration (Cmin) for Figitumumab</measure>
    <time_frame>Cycle 1 (Day 1 [predose], Day 2 [1 hour after end of infusion] ), Cycles 2, 4, 6 (predose), Cycle 5 (predose, 1 hour after end of infusion) for figi plus erlo group; Cycles 1, 2,4 (predose) for erlo, then figi group</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Positive for Total Anti-drug Antibodies (ADA)</measure>
    <time_frame>Cycles 1, 2, 4 (predose), End of Treatment ([EOT] 21-28 days after last dose), about 150 days after last figi dose for figi plus erlo group; Cycles 1, 2, 4 (predose), EOT, about 150 days after last figi dose for erlo, then figi group</time_frame>
    <description>ADAs are immunogenicity indicators to figitumumab. Participants reporting positive for ADAs are indicated by an endpoint titer of no less than 6.64.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Counts of Circulating Tumor Cell (CTC) Expressing Positive Insulin-Like Growth Factor 1 Receptor (IGF-1R)</measure>
    <time_frame>Baseline, Cycle 2 Day 1 (predose) and EOT (21-28 days after last dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Euro Quality of Life (EQ-5D)- Health State Profile Utility at Cycles 2, 3, Then Every Other Cycle and EOT (21-28 Days After Last Dose)</measure>
    <time_frame>Baseline (Cycle 1 Day 1 predose), Cycles 2, 3 (Day 1), every other cycle and EOT (21-28 days after last dose)</time_frame>
    <description>EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) at Cycles 2, 3, and Then Every Odd Cycle Starting With Cycle 5 and EOT (21-28 Days After Last Dose)</measure>
    <time_frame>Baseline (Cycle 1 Day 1 predose), Cycles 2, 3 (Day 1), every odd cycle starting with Cycle 5 and EOT (21-28 days after last dose)</time_frame>
    <description>EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions use 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13) Score at Cycles 2, 3, and Then Every Odd Cycle Starting With Cycle 5, and EOT (21-28 Days After Last Dose)</measure>
    <time_frame>Baseline (Cycle 1 Day 1 predose), Cycles 2, 3 (Day 1), every odd cycle starting with Cycle 5 and EOT (21-28 days after last dose)</time_frame>
    <description>QLQ-LC13 consists of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprise 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">583</enrollment>
  <condition>Carcinoma, Large Cell</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Carcinoma, Squamous Cell</condition>
  <condition>Carcinoma, Adenosquamous Cell</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The CP 751,871 treatment in combination with erlotinib will be given in three week cycles.
CP 751,871 (20 mg/kg) + erlotinib (150 mg/day) CP 751,871 will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP 751,871 (Figitumumab)</intervention_name>
    <description>CP 751,871 (20 mg/kg) will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib (one tablet of 150 mg/day PO).</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non small cell lung cancer with a primary histology of squamous cell, large cell or
             adenosquamous carcinoma. At least 1 measurable lesion, as defined by RECIST.

        Exclusion Criteria:

          -  Primary NSCLC adenocarcinoma and its subtypes or unknown/unspecified histology.

          -  Prior Erlotinib therapy.

          -  Prior anti IGF IR based investigational therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lakeport</city>
        <state>California</state>
        <zip>95453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Westlake Valley</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lafayette</city>
        <state>Colorado</state>
        <zip>80026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Conyers</city>
        <state>Georgia</state>
        <zip>30094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cumming</city>
        <state>Georgia</state>
        <zip>30041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <zip>30096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lake Spivey</city>
        <state>Georgia</state>
        <zip>30236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beech Grove</city>
        <state>Indiana</state>
        <zip>46107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <state>Iowa</state>
        <zip>50701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Albany</city>
        <state>Mississippi</state>
        <zip>38652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908-0334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908-0716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gloucester</city>
        <state>Virginia</state>
        <zip>23601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glouster</city>
        <state>Virginia</state>
        <zip>23061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Williamsburg</city>
        <state>Virginia</state>
        <zip>23185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wheeling</city>
        <state>West Virginia</state>
        <zip>26003-6300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cody</city>
        <state>Wyoming</state>
        <zip>82414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20230 -130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20231 -050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Higienopolis</city>
        <state>Sao Paulo/ Brazil</state>
        <zip>01224-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santo André</city>
        <state>SP</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01221-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01224-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01219-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Independencia</city>
        <state>Santiago, RM</state>
        <zip>8380455</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kutna Hora</city>
        <zip>284 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nova Ves pod Plesi</city>
        <zip>26204</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 8</city>
        <zip>180 81</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tabor</city>
        <zip>390 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rennes</city>
        <state>Cedex 9</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>BREST Cedex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lille</city>
        <zip>59020 Cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Marseille Cedex 09</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Marseille Cedex 20</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saint Pierre la Réunion Cedex</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St Priest En Jarez Cedex</city>
        <zip>42277</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Heraklion</city>
        <state>Crete</state>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Larisa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1525</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Matrahaza</city>
        <zip>H-3233</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>13230</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Surabaya</city>
        <state>East Java</state>
        <zip>60286</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dublin 24</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aviano (PN)</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cattolica (RN)</city>
        <zip>47841</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orbassano (TO)</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rimini</city>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>LV 1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>LV 1079</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-108</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-215</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-357</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rybnik</city>
        <zip>44-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wodzislaw Sl.</city>
        <zip>44-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Iasi</city>
        <zip>700106</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Krasnodar</city>
        <zip>350040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>143423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sochi</city>
        <zip>354057</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>L'hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08097</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Basel</city>
        <zip>CH-4058</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>CH-4101 Bruderholz</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taoyuan County</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Donetsk</city>
        <zip>83092</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sumy</city>
        <zip>40005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Indonesia</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4021018&amp;StudyName=Trial%20Of%20CP-751%2C%20871%20And%20Erlotinib%20In%20Refractory%20Lung%20Cancer</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <results_first_submitted>April 26, 2013</results_first_submitted>
  <results_first_submitted_qc>July 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 24, 2013</results_first_posted>
  <disposition_first_submitted>April 22, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 17, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 28, 2011</disposition_first_posted>
  <last_update_submitted>July 22, 2013</last_update_submitted>
  <last_update_submitted_qc>July 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IGR-1R</keyword>
  <keyword>Non small cell lung cancer</keyword>
  <keyword>CP-751</keyword>
  <keyword>871</keyword>
  <keyword>Figitumumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Large Cell</mesh_term>
    <mesh_term>Carcinoma, Adenosquamous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Figitumumab + Erlotinib (Randomized to and Treated With)</title>
          <description>Figitumumab ( [CP-751,871], figi) was given in combination with erlotinib (erlo) in 3-week cycles. Figitumumab 20 milligram/kilogram (mg/kg) was administered as an intravenous (IV) infusion on Days 1 and 2 in Cycle 1, and on Day 1 every 3 weeks (from Day 1) thereafter. Erlotinib was taken as 150 milligram (mg) daily at least 1 hour before or 2 hours after the ingestion of food.</description>
        </group>
        <group group_id="P2">
          <title>Erlotinib (Randomized to and Treated With)</title>
          <description>Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food.</description>
        </group>
        <group group_id="P3">
          <title>Randomized to Figi + Erlo Arm But Treated Only With Erlo</title>
          <description>Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food.</description>
        </group>
        <group group_id="P4">
          <title>Erlotinib, Then Figitumumab</title>
          <description>Figitumumab 20 mg/kg was given as a single-agent therapy to participants who had disease progression on erlotinib alone. Figitumumab was administered in 3-week cycles as IV infusion on study Days 1 and 2 in Cycle 1, and on Day 1 every 3 weeks (from Day 1) thereafter.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Before Progression on Erlotinib</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="292"/>
                <participants group_id="P2" count="290"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0">Participants treated with erlo alone who subsequently received figi upon disease progression.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="289"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="292"/>
                <participants group_id="P2" count="290"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="167"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Switched to figitumumab</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Progression on Erlotinib</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="83"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="71"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Figitumumab + Erlotinib (as Randomized)</title>
          <description>Figitumumab (20 mg/kg) in combination with erlotinib (150 mg/day) was given in 3-week cycles. Figitumumab was administered as an IV infusion on study Days 1 and 2 in Cycle 1, and on Day 1 every 3 weeks (from Day 1) thereafter. Erlotinib was taken as 150 mg at least 1 hour before or 2 hours after the ingestion of food. Intent-to-treat population according to randomization was analyzed.</description>
        </group>
        <group group_id="B2">
          <title>Erlotinib (as Randomized)</title>
          <description>Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food. Intent-to-treat population according to randomization was analyzed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="293"/>
            <count group_id="B2" value="290"/>
            <count group_id="B3" value="583"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="228"/>
                    <measurement group_id="B2" value="225"/>
                    <measurement group_id="B3" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>The time from date of randomization to date of death due to any cause. For participants who were alive, overall survival was censored at the last contact.</description>
        <time_frame>Baseline, assessed every cycle until disease progression and then every 4 weeks until death, up to 30.65 months</time_frame>
        <population>Full (intent-to-treat) analysis set, which included all participants randomized regardless of treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Figitumumab + Erlotinib</title>
            <description>Figitumumab (20 mg/kg) in combination with erlotinib (150 mg/day) was given in 3-week cycles. Figitumumab was administered as an IV infusion on study Days 1 and 2 in Cycle 1, and on Day 1 every 3 weeks (from Day 1) thereafter. Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food.</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib</title>
            <description>Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The time from date of randomization to date of death due to any cause. For participants who were alive, overall survival was censored at the last contact.</description>
          <population>Full (intent-to-treat) analysis set, which included all participants randomized regardless of treatment received.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="4.8" upper_limit="6.7"/>
                    <measurement group_id="O2" value="6.2" lower_limit="5.8" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated using log-rank test stratified by gender (Male or Female), Eastern Cooperative Oncology Group (ECOG) performance status (less than or equal to [=&lt;1] or 2), and region (United States/Canada, European Union, rest of world). The stratified Cox proportional hazards model was fitted to estimate the hazard ratio, using the same stratification variables as above.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <p_value_desc>One-sided significance level at alpha=0.024 was used. Two-sided p-value was reported.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Nominal p-values were reported without adjustment for the interim analysis.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.091</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.909</ci_lower_limit>
            <ci_upper_limit>1.310</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>Time from randomization to date of first documentation of progression or death due to any cause, whichever came first. Participants last known to be alive and progression-free, who had a baseline and at least 1 on-study disease assessment, were censored at last disease assessment verifying lack of progression. Progression was determined by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, as a 20% increase in the sum of the longest diameter of target lesions, or target lesions over nadir, unequivocal progression of non-target disease, or the appearance of new lesions.</description>
        <time_frame>Baseline, 6, 9, 12, 15, 18 weeks after randomization, thereafter assessed every 6 weeks until disease progression during treatment (or every 8 weeks until disease progression during off-treatment), up to 29.7 months</time_frame>
        <population>Full (intent-to-treat) analysis set, which included all participants randomized regardless of treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Figitumumab + Erlotinib</title>
            <description>Figitumumab (20 mg/kg) in combination with erlotinib (150 mg/day) was given in 3-week cycles. Figitumumab was administered as an IV infusion on study Days 1 and 2 in Cycle 1, and on Day 1 every 3 weeks (from Day 1) thereafter. Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food.</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib</title>
            <description>Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>Time from randomization to date of first documentation of progression or death due to any cause, whichever came first. Participants last known to be alive and progression-free, who had a baseline and at least 1 on-study disease assessment, were censored at last disease assessment verifying lack of progression. Progression was determined by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, as a 20% increase in the sum of the longest diameter of target lesions, or target lesions over nadir, unequivocal progression of non-target disease, or the appearance of new lesions.</description>
          <population>Full (intent-to-treat) analysis set, which included all participants randomized regardless of treatment received.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.9" upper_limit="2.6"/>
                    <measurement group_id="O2" value="2.6" lower_limit="2.1" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated using log-rank test stratified by gender (Male or Female), ECOG performance status (less than or equal to [=&lt;1] or 2), and region (United States/Canada, European Union, rest of world). The stratified Cox proportional hazards model was fitted to estimate the hazard ratio, using the same stratification variables as above.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.426</p_value>
            <p_value_desc>One-sided significance level at alpha=0.001 was used. Two-sided p-value was reported.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.075</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.898</ci_lower_limit>
            <ci_upper_limit>1.287</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Objective Response</title>
        <description>Percentage of participants with objective response (OR) based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. CR are defined as complete disappearance of all lesions (target and/or non target). PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.</description>
        <time_frame>Baseline, 6, 9, 12, 15, 18 weeks after randomization, thereafter assessed every 6 weeks until disease progression during treatment (or every 8 weeks until disease progression during off-treatment), up to 29.7 months</time_frame>
        <population>Full (intent-to-treat) analysis set, which included all participants randomized regardless of treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Figitumumab + Erlotinib</title>
            <description>Figitumumab (20 mg/kg) in combination with erlotinib (150 mg/day) was given in 3-week cycles. Figitumumab was administered as an IV infusion on study Days 1 and 2 in Cycle 1, and on Day 1 every 3 weeks (from Day 1) thereafter. Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food.</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib</title>
            <description>Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Objective Response</title>
          <description>Percentage of participants with objective response (OR) based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. CR are defined as complete disappearance of all lesions (target and/or non target). PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.</description>
          <population>Full (intent-to-treat) analysis set, which included all participants randomized regardless of treatment received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="3.2" upper_limit="8.7"/>
                    <measurement group_id="O2" value="3.8" lower_limit="1.9" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.338</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in response rates</param_type>
            <param_value>1.668</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) for Figitumumab</title>
        <time_frame>Cycle 1 (Day 1 [predose], Day 2 [1 hour after end of infusion] ), Cycles 2, 4, 6 (predose), Cycle 5 (predose, 1 hour after end of infusion) for figi plus erlo group; Cycles 1, 2,4 (predose) for erlo, then figi group</time_frame>
        <population>Due to futility, the study was terminated early; therefore pharmacokinetic data were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Figitumumab + Erlotinib, and Erlotinib Then Figitumumab</title>
            <description>Participants who received figitumumab (20 mg/kg), whether figitumumab was given in combination with erlotinib (150 mg/day) from the beginning or figitumumab was given after disease progression with erlotinib (150 mg/day) alone. Figitumumab was administered as an IV infusion on study Days 1 and 2 in Cycle 1, and on Day 1 every 3 weeks (from Day 1) thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) for Figitumumab</title>
          <population>Due to futility, the study was terminated early; therefore pharmacokinetic data were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Observed Plasma Trough Concentration (Cmin) for Figitumumab</title>
        <time_frame>Cycle 1 (Day 1 [predose], Day 2 [1 hour after end of infusion] ), Cycles 2, 4, 6 (predose), Cycle 5 (predose, 1 hour after end of infusion) for figi plus erlo group; Cycles 1, 2,4 (predose) for erlo, then figi group</time_frame>
        <population>Due to futility, the study was terminated early; therefore pharmacokinetic data were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Figitumumab + Erlotinib, and Erlotinib Then Figitumumab</title>
            <description>Participants who received figitumumab (20 mg/kg), whether figitumumab was given in combination with erlotinib (150 mg/day) from the beginning or figitumumab was given after disease progression with erlotinib (150 mg/day) alone. Figitumumab was administered as an IV infusion on study Days 1 and 2 in Cycle 1, and on Day 1 every 3 weeks (from Day 1) thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Observed Plasma Trough Concentration (Cmin) for Figitumumab</title>
          <population>Due to futility, the study was terminated early; therefore pharmacokinetic data were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Positive for Total Anti-drug Antibodies (ADA)</title>
        <description>ADAs are immunogenicity indicators to figitumumab. Participants reporting positive for ADAs are indicated by an endpoint titer of no less than 6.64.</description>
        <time_frame>Cycles 1, 2, 4 (predose), End of Treatment ([EOT] 21-28 days after last dose), about 150 days after last figi dose for figi plus erlo group; Cycles 1, 2, 4 (predose), EOT, about 150 days after last figi dose for erlo, then figi group</time_frame>
        <population>Analysis population included all participants treated with figi. Data are combined for &quot;figi+erlo&quot; and &quot;erlo then figi&quot; because the objective was to report any participants with positive ADA after exposure to figi regardless of figi administration order, rather comparison of these 2 treatment groups. N=number of participants evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Figitumumab + Erlotinib, and Erlotinib Then Figitumumab</title>
            <description>Participants who received figitumumab (20 mg/kg), whether figitumumab was given in combination with erlotinib (150 mg/day) from the beginning or figitumumab was given after disease progression with erlotinib (150 mg/day) alone. Figitumumab was administered as an IV infusion on study Days 1 and 2 in Cycle 1, and on Day 1 every 3 weeks (from Day 1) thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Positive for Total Anti-drug Antibodies (ADA)</title>
          <description>ADAs are immunogenicity indicators to figitumumab. Participants reporting positive for ADAs are indicated by an endpoint titer of no less than 6.64.</description>
          <population>Analysis population included all participants treated with figi. Data are combined for &quot;figi+erlo&quot; and &quot;erlo then figi&quot; because the objective was to report any participants with positive ADA after exposure to figi regardless of figi administration order, rather comparison of these 2 treatment groups. N=number of participants evaluable.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="360"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Counts of Circulating Tumor Cell (CTC) Expressing Positive Insulin-Like Growth Factor 1 Receptor (IGF-1R)</title>
        <time_frame>Baseline, Cycle 2 Day 1 (predose) and EOT (21-28 days after last dose)</time_frame>
        <population>Due to futility, the study was terminated early; therefore biomarker results were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Figitumumab + Erlotinib, and Erlotinib Then Figitumumab</title>
            <description>Participants who received figitumumab (20 mg/kg), whether figitumumab was given in combination with erlotinib (150 mg/day) from the beginning or figitumumab was given after disease progression with erlotinib (150 mg/day) alone. Figitumumab was administered as an IV infusion on study Days 1 and 2 in Cycle 1, and on Day 1 every 3 weeks (from Day 1) thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Counts of Circulating Tumor Cell (CTC) Expressing Positive Insulin-Like Growth Factor 1 Receptor (IGF-1R)</title>
          <population>Due to futility, the study was terminated early; therefore biomarker results were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Euro Quality of Life (EQ-5D)- Health State Profile Utility at Cycles 2, 3, Then Every Other Cycle and EOT (21-28 Days After Last Dose)</title>
        <description>EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
        <time_frame>Baseline (Cycle 1 Day 1 predose), Cycles 2, 3 (Day 1), every other cycle and EOT (21-28 days after last dose)</time_frame>
        <population>Due to futility, the study was terminated early; therefore EQ-5D data were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Figitumumab + Erlotinib</title>
            <description>Figitumumab (20 mg/kg) in combination with erlotinib (150 mg/day) was given in 3-week cycles. Figitumumab was administered as an IV infusion on study Days 1 and 2 in Cycle 1, and on Day 1 every 3 weeks (from Day 1) thereafter. Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food.</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib</title>
            <description>Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Euro Quality of Life (EQ-5D)- Health State Profile Utility at Cycles 2, 3, Then Every Other Cycle and EOT (21-28 Days After Last Dose)</title>
          <description>EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
          <population>Due to futility, the study was terminated early; therefore EQ-5D data were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) at Cycles 2, 3, and Then Every Odd Cycle Starting With Cycle 5 and EOT (21-28 Days After Last Dose)</title>
        <description>EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions use 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.</description>
        <time_frame>Baseline (Cycle 1 Day 1 predose), Cycles 2, 3 (Day 1), every odd cycle starting with Cycle 5 and EOT (21-28 days after last dose)</time_frame>
        <population>This outcome measure was added in Protocol Amendment 3 (28 January 2010). However, data were not collected as the majority of the subjects had already been enrolled prior to this amendment and the study was terminated shortly thereafter (02 March 2010).</population>
        <group_list>
          <group group_id="O1">
            <title>Figitumumab + Erlotinib</title>
            <description>Figitumumab (20 mg/kg) in combination with erlotinib (150 mg/day) was given in 3-week cycles. Figitumumab was administered as an IV infusion on study Days 1 and 2 in Cycle 1, and on Day 1 every 3 weeks (from Day 1) thereafter. Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food.</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib</title>
            <description>Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) at Cycles 2, 3, and Then Every Odd Cycle Starting With Cycle 5 and EOT (21-28 Days After Last Dose)</title>
          <description>EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions use 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.</description>
          <population>This outcome measure was added in Protocol Amendment 3 (28 January 2010). However, data were not collected as the majority of the subjects had already been enrolled prior to this amendment and the study was terminated shortly thereafter (02 March 2010).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13) Score at Cycles 2, 3, and Then Every Odd Cycle Starting With Cycle 5, and EOT (21-28 Days After Last Dose)</title>
        <description>QLQ-LC13 consists of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprise 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.</description>
        <time_frame>Baseline (Cycle 1 Day 1 predose), Cycles 2, 3 (Day 1), every odd cycle starting with Cycle 5 and EOT (21-28 days after last dose)</time_frame>
        <population>This outcome measure was added in Protocol Amendment 3 (28 January 2010). However, data were not collected as the majority of the subjects had already been enrolled prior to this amendment and the study was terminated shortly thereafter (02 March 2010).</population>
        <group_list>
          <group group_id="O1">
            <title>Figitumumab + Erlotinib</title>
            <description>Figitumumab (20 mg/kg) in combination with erlotinib (150 mg/day) was given in 3-week cycles. Figitumumab was administered as an IV infusion on study Days 1 and 2 in Cycle 1, and on Day 1 every 3 weeks (from Day 1) thereafter. Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food.</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib</title>
            <description>Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13) Score at Cycles 2, 3, and Then Every Odd Cycle Starting With Cycle 5, and EOT (21-28 Days After Last Dose)</title>
          <description>QLQ-LC13 consists of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprise 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.</description>
          <population>This outcome measure was added in Protocol Amendment 3 (28 January 2010). However, data were not collected as the majority of the subjects had already been enrolled prior to this amendment and the study was terminated shortly thereafter (02 March 2010).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study. All treated subjects were analyzed for AEs and SAEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Figitumumab + Erlotinib</title>
          <description>Figitumumab (20 mg/kg) in combination with erlotinib (150 mg/day) was given in 3-week cycle. Figitumumab was administered as an IV infusion on study Days 1 and 2 in Cycle 1, and on Day 1 every three weeks (from Day 1) thereafter. Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food.</description>
        </group>
        <group group_id="E2">
          <title>Erlotinib</title>
          <description>Erlotinib was taken as 150 mg daily at least 1 hour before or 2 hours after the ingestion of food.</description>
        </group>
        <group group_id="E3">
          <title>Erlotinib, Then Figitumumab</title>
          <description>Figitumumab (20 mg/kg) was given as a single agent after participants had disease progression on erlotinib alone. Figitumumab was given in 3-week cycles as IV infusion on study Days 1 and 2 in Cycle 1, and on Day 1 every 3 weeks (from Day 1) thereafter.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pericarditis constrictive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Tracheo-oesophageal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness bilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fungaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Collapse of lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Band neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Myocardial strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Renal function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sebaceous carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Alveolitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dyspnoea at rest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hydropneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oesophagobronchial fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="265" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="265" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haematotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cushing’s syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal sensation in eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Eye inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Keratoconjunctivitis sicca</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ocular icterus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ocular toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Aerophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Chapped lips</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastric dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gingival disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oesophageal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Salivary gland disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tooth socket haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Medical device pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cytolytic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Acne pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Eye infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nail bed infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Omphalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Respiratory moniliasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sputum purulent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Eschar</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tracheal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blood urea nitrogen/creatinine ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Brain natriuretic peptide increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Clostridium test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nutritional condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Protein urine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Prothrombin time shortened</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Renal function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Respiratory rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypermagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypercreatinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tumour invasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Movement disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Myotonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bradyphrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dysthymic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oedema genital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Scrotal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bronchial disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hydropneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oesophagobronchial fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Respiratory tract haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hair texture abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nail bed bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nail toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Onychalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Onychomadesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Palmar erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Scar pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin plaque</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Xeroderma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

